Loxo Oncology was founded in 2013 and is headquartered in Stamford, US
Report incorrect company information
Key People/Management at Loxo Oncology
Josh Bilenker
Founder, President & CEO
Nisha Nanda
VP of Development Strategy
Jacob Van Naarden
Chief Business Officer
Jennifer Burstein
VP of Finance
Report incorrect company information
Loxo Oncology Office Locations
Loxo Oncology has offices in Stamford and South San Francisco
Stamford, US (HQ)
281 Tresser Blvd
South San Francisco, US
520 400 Oyster Point Blvd
Report incorrect company information
Loxo Oncology Financials and Metrics
Loxo Oncology Financials
| USD | |
|---|---|
Net income (Q1, 2018) | (3.6 m) |
EBIT (Q1, 2018) | (5.8 m) |
Market capitalization (22-Jun-2018) | 5.5 b |
Closing share price (22-Jun-2018) | 183.8 |
Cash (31-Mar-2018) | 103.8 m |
Loxo Oncology's current market capitalization is $5.5 b.
- Source: SEC Filings
Annual
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
General and administrative expense | 583 k | 10.5 m | 14.9 m |
R&D expense | 323 k | 14 m | 58.3 m |
Operating expense total | 906 k | 24.5 m | 73.2 m |
Net Income | (10.3 m) | (35.9 m) | (72.4 m) |
- Source: SEC Filings
Annual
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (20.7 m) | (35.9 m) | (72.4 m) |
Depreciation and Amortization | 1 k | 17 k | 77 k |
Accounts Payable | 18 k | 30 k | 792 k |
Cash From Operating Activities | (2.8 m) | (30.2 m) | (51.3 m) |
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.1 m) | (8.8 m) | (11.6 m) | (15.9 m) | (17.7 m) | (24.5 m) | (54.9 m) | (3.6 m) | ||
Depreciation and Amortization | 21 k | 48 k | 80 k | |||||||
Accounts Payable | 207 k | 285 k | 415 k | 731 k | 758 k | 677 k | 1 m | 192 k | 1.1 m | 1.8 m |
Cash From Operating Activities | (26.7 m) | (50.5 m) | 109.8 m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.9 x |
Report incorrect company information
Loxo Oncology Online and Social Media Presence
Report incorrect company information
Loxo Oncology News and Updates
June 02, 2018
Loxo Oncology posts improved results for newest cancer drug
CHICAGO, June 2 (Reuters) - An experimental cancer drug from
Loxo Oncology performed even better in patients with a
rare mutation of the RET gene than previously reported,
according to updated results from an early stage clinical trial
presented on Saturday.
Report incorrect company information